Hengehold Capital Management LLC lessened its holdings in Humana Inc (NYSE:HUM) by 32.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 998 shares of the insurance provider’s stock after selling 481 shares during the quarter. Hengehold Capital Management LLC’s holdings in Humana were worth $366,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of HUM. Endurance Wealth Management Inc. lifted its position in Humana by 354.5% in the third quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after acquiring an additional 78 shares during the last quarter. Evoke Wealth LLC purchased a new position in shares of Humana during the third quarter worth about $26,000. Quest Capital Management Inc. ADV purchased a new position in shares of Humana during the third quarter worth about $30,000. Penserra Capital Management LLC acquired a new stake in shares of Humana during the third quarter worth about $31,000. Finally, Psagot Investment House Ltd. acquired a new stake in shares of Humana during the third quarter worth about $35,000. 94.50% of the stock is currently owned by hedge funds and other institutional investors.

In other Humana news, Director James J. /Ky Obrien sold 2,500 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $345.21, for a total value of $863,025.00. Also, insider Timothy S. Huval sold 7,373 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $348.60, for a total transaction of $2,570,227.80. Following the completion of the transaction, the insider now directly owns 14,548 shares in the company, valued at $5,071,432.80. The disclosure for this sale can be found here. Insiders have sold 45,294 shares of company stock valued at $15,894,412 in the last 90 days. Company insiders own 0.54% of the company’s stock.

A number of analysts recently issued reports on HUM shares. Barclays upped their target price on Humana from $327.00 to $358.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Mizuho assumed coverage on Humana in a research report on Thursday, October 17th. They set a “buy” rating and a $316.00 price target on the stock. Goldman Sachs Group reaffirmed a “buy” rating and set a $425.00 price target on shares of Humana in a research report on Friday, January 3rd. Morgan Stanley reiterated a “buy” rating and issued a $360.00 price objective (up previously from $337.00) on shares of Humana in a research note on Monday, November 18th. Finally, Wells Fargo & Co reissued an “overweight” rating and issued a $400.00 price objective (up from $338.00) on shares of Humana in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $361.31.

HUM stock traded down $7.53 during trading on Friday, hitting $356.05. The company had a trading volume of 676,498 shares, compared to its average volume of 795,706. The firm has a market cap of $48.43 billion, a PE ratio of 18.92, a price-to-earnings-growth ratio of 1.43 and a beta of 0.92. Humana Inc has a 1-year low of $225.65 and a 1-year high of $376.39. The firm has a 50-day moving average price of $362.35 and a 200-day moving average price of $308.36. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.46.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a return on equity of 22.32% and a net margin of 4.06%. The firm had revenue of $16.24 billion during the quarter, compared to the consensus estimate of $16.15 billion. During the same period in the prior year, the business earned $4.58 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. Sell-side analysts anticipate that Humana Inc will post 17.77 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.